Shots:

• The marketing authorization is based on P-IIIb EXPEDITION-8 study assessing Maviret in 280 treatment-naive chronic HCV patients with compensated cirrhosis across all major genotypes (GT1-6) for 8wks.
• The P-IIIb EXPEDITION-8 study resulted in @8wks. 97.9% GT1- 2- 4- 5 & 6 patients achieved a sustained virologic response 12wks. (SVR12); no case of virologic failures and discontinued treatment were observed
• Maviret is a combination of NS3/4A protease & NS5A inhibitor and is an 8-week- pan-genotypic option (GT1-6) for patients who are new to treatment and without cirrhosis and for GT1- 2- 4- 5 and 6 patients who are new to treatment with compensated cirrhosis

Click here to­ read full press release/ article

Ref: AbbVie | Image:AbbVie